Tyra Biosciences, Inc. (TYRA)

NMS – Цена в реальном времени. Валюта: USD

31.88

+0.94 (3.04%)

При закрытии: Jun 26, 2026, 4:00 PM EDT

31.88

-0.00 (-0.00%)

После закрытия: Jun 26, 2026, 4:36 PM EDT

21.05.2026

TYRA BIOSCIENCES AND BCAN ESTABLISH MAY 21 AS UPPER TRACT UROTHELIAL CANCER (UTUC) AWARENESS DAY

-Collaboration aims to raise awareness of UTUC and the need for continued innovation for patients living with this rare and difficult-to-treat cancer- CARLSBAD, Calif., May 21, 2026 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced the establishment of Upper Tract Urothelial Cancer (UTUC) Awareness Day, in collaboration with the Bladder Cancer Advocacy Network (BCAN).

13.05.2026

Tyra Biosciences, Inc. (TYRA) Presents at Bank of America Global Healthcare Conference 2026 Transcript

13.05.2026

Tyra Biosciences Reports First Quarter 2026 Financial Results and Recent Highlights

- Advanced "dabogratinib 3x3" strategy to pursue 3 late-stage clinical studies in LG-UTUC, IR NMIBC and ACH - - First LG-UTUC patient dosed with dabogratinib in SURF303; initial results expected in 2027 - - Initial Ph2 data readout from SURF302 expected in August 2026 (n>20 enrolled to date) - - Initial Ph2 data readout from safety sentinel cohort in BEACH301 expected in Q4 2026 (4th dose level cleared) - - Cash, cash equivalents and marketable securities of $383.5 million at Q1 2026; runway into 2H 2028 - CARLSBAD, Calif., May 13, 2026 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today reported financial results for the first quarter ended March 31, 2026, and highlighted recent corporate progress.

07.05.2026

Tyra Biosciences to Participate in Upcoming Investor Conferences

CARLSBAD, Calif., May 7, 2026 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced participation at the following investor conferences: BofA Securities Health Care Conference 2026 Format: Virtual fireside chat and one-on-one investor meetingsPresentation Date/Time: Wednesday, May 13, 2026 at 10:40 am PTLocation: Las Vegas, NV TD Cowen's 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA Format: Fireside chat with Tyler van BurenPresentation Date/Time: Tuesday, May 26, 2026 at 2:00 pm ETLocation: Virtual Jefferies Global Healthcare Conference Format: Hybrid fireside chat and one-on-one investor meetingsPresentation Date/Time: Wednesday, June 3, 2026 at 3:45 pm ETLocation: New York, NY A live webcast of the presentations can be accessed by visiting the "For Investors" page on the Tyra Biosciences website and will be available for replay following the event.

17.04.2026

Tyra Biosciences Announces Appointment of Habib Dable to its Board of Directors

-Seasoned biopharmaceutical leader brings deep commercial and strategic expertise to support TYRA's next phase of growth- CARLSBAD, Calif., April 17, 2026 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced the appointment of Habib Dable to its Board of Directors.

20.03.2026

This Biotech Stock Has Surged 250% in a Year as One Investor Discloses $10 Million New Position

Boone Capital added 398,482 shares of TYRA in the fourth quarter. The quarter-end position value rose by $10.48 million as a result of the new stake.

02.03.2026

Tyra Biosciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Highlights

- Launched "dabogratinib 3x3" strategy to pursue 3 late-stage clinical studies in LG-UTUC, IR NMIBC and ACH, 3 potential blockbuster indications - - Interim Ph2 data readouts on track: SURF302 expected by end of 1H'26 and BEACH301 in 2H '26 - - Cash, cash equivalents and marketable securities of $256.0 million at Q4 2025; runway through at least 2027 - CARLSBAD, Calif., March 2, 2026 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today reported financial results for the fourth quarter and full-year ended December 31, 2025 and highlighted recent corporate progress.

Видео

No Data

There is no data to display

Пресс-релизы

21.05.2026

TYRA BIOSCIENCES AND BCAN ESTABLISH MAY 21 AS UPPER TRACT UROTHELIAL CANCER (UTUC) AWARENESS DAY

13.05.2026

Tyra Biosciences Reports First Quarter 2026 Financial Results and Recent Highlights

17.04.2026

Tyra Biosciences Announces Appointment of Habib Dable to its Board of Directors

02.03.2026

Tyra Biosciences, Inc. (TYRA)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Tyra Biosciences, Inc. (TYRA)

TYRA BIOSCIENCES AND BCAN ESTABLISH MAY 21 AS UPPER TRACT UROTHELIAL CANCER (UTUC) AWARENESS DAY

Tyra Biosciences, Inc. (TYRA) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Tyra Biosciences Reports First Quarter 2026 Financial Results and Recent Highlights

Tyra Biosciences to Participate in Upcoming Investor Conferences

Tyra Biosciences Announces Appointment of Habib Dable to its Board of Directors

This Biotech Stock Has Surged 250% in a Year as One Investor Discloses $10 Million New Position

Tyra Biosciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Highlights

Видео

No Data

Пресс-релизы

TYRA BIOSCIENCES AND BCAN ESTABLISH MAY 21 AS UPPER TRACT UROTHELIAL CANCER (UTUC) AWARENESS DAY

Tyra Biosciences Reports First Quarter 2026 Financial Results and Recent Highlights

Tyra Biosciences Announces Appointment of Habib Dable to its Board of Directors

Tyra Biosciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Highlights

TYRA BIOSCIENCES AND BCAN ESTABLISH MAY 21 AS UPPER TRACT UROTHELIAL CANCER (UTUC) AWARENESS DAY

Tyra Biosciences, Inc. (TYRA) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Tyra Biosciences Reports First Quarter 2026 Financial Results and Recent Highlights

Tyra Biosciences to Participate in Upcoming Investor Conferences

Tyra Biosciences Announces Appointment of Habib Dable to its Board of Directors

This Biotech Stock Has Surged 250% in a Year as One Investor Discloses $10 Million New Position

Tyra Biosciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Highlights

Видео

No Data

Пресс-релизы

TYRA BIOSCIENCES AND BCAN ESTABLISH MAY 21 AS UPPER TRACT UROTHELIAL CANCER (UTUC) AWARENESS DAY

Tyra Biosciences Reports First Quarter 2026 Financial Results and Recent Highlights

Tyra Biosciences Announces Appointment of Habib Dable to its Board of Directors

Tyra Biosciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Highlights

Search stocks

Tyra Biosciences, Inc. (TYRA)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Tyra Biosciences, Inc. (TYRA)

TYRA BIOSCIENCES AND BCAN ESTABLISH MAY 21 AS UPPER TRACT UROTHELIAL CANCER (UTUC) AWARENESS DAY

Tyra Biosciences, Inc. (TYRA) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Tyra Biosciences Reports First Quarter 2026 Financial Results and Recent Highlights

Tyra Biosciences to Participate in Upcoming Investor Conferences

Tyra Biosciences Announces Appointment of Habib Dable to its Board of Directors

This Biotech Stock Has Surged 250% in a Year as One Investor Discloses $10 Million New Position

Tyra Biosciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Highlights

Видео

No Data

Пресс-релизы

TYRA BIOSCIENCES AND BCAN ESTABLISH MAY 21 AS UPPER TRACT UROTHELIAL CANCER (UTUC) AWARENESS DAY

Tyra Biosciences Reports First Quarter 2026 Financial Results and Recent Highlights

Tyra Biosciences Announces Appointment of Habib Dable to its Board of Directors

Tyra Biosciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Highlights

TYRA BIOSCIENCES AND BCAN ESTABLISH MAY 21 AS UPPER TRACT UROTHELIAL CANCER (UTUC) AWARENESS DAY

Tyra Biosciences, Inc. (TYRA) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Tyra Biosciences Reports First Quarter 2026 Financial Results and Recent Highlights

Tyra Biosciences to Participate in Upcoming Investor Conferences

Tyra Biosciences Announces Appointment of Habib Dable to its Board of Directors

This Biotech Stock Has Surged 250% in a Year as One Investor Discloses $10 Million New Position

Tyra Biosciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Highlights

Видео

No Data

Пресс-релизы

TYRA BIOSCIENCES AND BCAN ESTABLISH MAY 21 AS UPPER TRACT UROTHELIAL CANCER (UTUC) AWARENESS DAY

Tyra Biosciences Reports First Quarter 2026 Financial Results and Recent Highlights

Tyra Biosciences Announces Appointment of Habib Dable to its Board of Directors

Tyra Biosciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Highlights